|
1
|
Slootweg PJ and Eveson JW: Tumours of the
oral cavity and oropharynx. In: World Health Organization
Classification of TumoursPathology & Genetics of Head and Neck
Tumours. IARC Press; Lyon: pp. 166–167. 2005
|
|
2
|
Okura M, Aikawa T, Sawai N, Lida S and
Kogo M: Decision analysis and ent threshold in a management for the
N0 neck of the oral cavity carcinoma. Oral Oncol. 45:908–911. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lea J, Bachar G, Sawka AM, Lakra DC,
Gilbert RW, Irish JC, Brown DH, Gullane PJ and Goldstein DP:
Metastases to level IIb in squamous cell carcinoma of the oral
cavity: A systematic review and meta-analysis. Head Neck.
32:184–190. 2010.PubMed/NCBI
|
|
4
|
Fan S, Tang QL, Lin YJ, Chen WL, Li JS,
Huang ZQ, Yang ZH, Wang YY, Zhang DM, Wang HJ, et al: A review of
clinical and histological parameters associated with contralateral
neck metastases in oral squamous cell carcinoma. Int J Oral Sci.
3:180–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noguti J, De Moura CF, De Jesus GP, Da
Silva VH, Hossaka TA, Oshima CT and Ribeiro DA: Metastasis from
oral cancer: An overview. Cancer Genomics Proteomics. 9:329–336.
2012.PubMed/NCBI
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huber GF, Züllig L, Soltermann A, Roessle
M, Graf N, Haerle SK, Studer G, Jochum W, Moch H and Stoeckli SJ:
Down regulation of E-Cadherin (ECAD)-a predictor for occult
metastatic disease in sentinel node biopsy of early squamous cell
carcinomas of the oral cavity and oropharynx. BMC Cancer.
11:217:1–8. 2011. View Article : Google Scholar
|
|
9
|
Zhao Z, Ge J, Sun Y, Tian L, Lu J, Liu M
and Zhao Y: Is E-cadherin immunoexpression a prognostic factor for
head and neck squamous cell carcinoma (HNSCC)? A systematic review
and meta-analysis. Oral Oncol. 48:761–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thedieck C, Kuczyk M, Klingel K, Steiert
I, Müller CA and Klein G: Expression of Ksp-cadherin during kidney
development and in renal cell carcinoma. Br J Cancer. 92:2010–2017.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fluge Ø, Bruland O, Akslen LA, Lillehaug
JR and Varhaug JE: Gene expression in poorly differentiated
papillary thyroid carcinomas. Thyroid. 16:161–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sancisi V, Gandolfi G, Ragazzi M, Nicoli
D, Tamagnini I, Piana S and Ciarrocchi A: Cadherin 6 is a new RUNX2
target in TGF-β signalling pathway. PLoS One. 12:e754892013.
View Article : Google Scholar
|
|
13
|
Chu K, Cheng C J, Ye X, Lee YC, Zurita AJ,
Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, et al: Cadherin-11
promotes the metastasis of prostate cancer cells to bone. Mol
Cancer Res. 6:1259–1267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang CF, Lira C, Chu K, Bilen MA, Lee YC,
Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, et al: Cadherin-11
increases migration and invasion of prostate cancer cells and
enhances their interaction with osteoblasts. Cancer Res.
70:4580–4589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou YE, Hsieh MJ, Hsin CH, Chiang WL, Lai
YC, Lee YH, Huang SC, Yang SF and Lin CW: CD44 gene polymorphisms
and environmental factors on oral cancer susceptibility in Taiwan.
PLoS One. 9:e936922014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shakib PA, Ensani F, Abdirad A, Valizadeh
B, Seyedmajidi M and Sum S: CD44 and CD74: The promising candidates
for molecular targeted therapy in oral squamous cell carcinoma.
Dent Res J (Isfahan). 12:181–186. 2015.PubMed/NCBI
|
|
17
|
Joshua B, Kaplan MJ, Doweck I, Pai R,
Weissman IL, Prince ME and Ailles LE: Frequency of cells expressing
CD44, a head and neck cancer stem cell marker: Correlation with
tumor aggressiveness. Head Neck. 34:42–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Judd NP, Winkler AE, Murillo-Sauca O,
Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB and
Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer
aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene F and Trotti A: AJCC cancer staging manual. 7th edition.
Springer-Verlag; New York: pp. 347–377. 2010
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshihama R, Yamaguchi K, Imajyo I, Mine
M, Hiyake N, Akimoto N, Kobayashi Y, Chigita S, Kumamaru W,
Kiyoshima T, et al: Expression levels of SOX2, KLF4 and brachyury
transcription factors are associated with metastasis and poor
prognosis in oral squamous cell carcinoma. Oncol Lett.
11:1435–1446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang H, Liang J, Zhou J, Mi J, Ma K, Fan
Y, Ning J, Wang C, Wei X and Li E: Knockdown of RHOC by shRNA
suppresses invasion and migration of cholangiocellular carcinoma
cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal
transition. Mol Med Rep. 13:5255–5261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bradbury R, Jiang WG and Cui YX: MDM2 and
PSMA Play inhibitory roles in metastatic breast cancer cells
through regulation of matrix metalloproteinases. Anticancer Res.
36:1143–1151. 2016.PubMed/NCBI
|
|
24
|
Mendonsa AM, VanSaun MN, Ustione A, Piston
DW, Fingleton BM and Gorden DL: Host and tumor derived MMP13
regulate extravasation and establishment of colorectal metastases
in the liver. Mol Cancer. 14:492015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonecchi R, Galliera E, Borroni EM, Corsi
MM, Locati M and Mantovani A: Chemokines and chemokine receptors:
An overview. Front Biosci. 14:540–551. 2009. View Article : Google Scholar
|
|
26
|
Chinn SB and Myers JN: Oral cavity
carcinoma: current management, controversies, and future
directions. J Clin Oncol. 33:3269–3276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ashaie MA and Chowdhury EH: Cadherins: The
superfamily critically involved in breast cancer. Curr Pharm Des.
22:616–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou J, Tao D, Xu Q, Gao Z and Tang D:
Expression of E-cadherin and vimentin in oral squamous cell
carcinoma. Int J Clin Exp Pathol. 8:3150–3154. 2015.PubMed/NCBI
|
|
29
|
Alaee M, Danesh G and Pasdar M:
Plakoglobin reduces the in vitro growth, migration and invasion of
ovarian cancer cells expressing N-cadherin and mutant p53. PLoS
One. 11:e01543232016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paul R, Necknig U, Busch R, Ewing CM,
Hartung R and Isaacs WB: Cadherin-6: A new prognostic marker for
renal cell carcinoma. J Uro. 171:97–101. 2004. View Article : Google Scholar
|
|
31
|
Satcher RL, Pan T, Bilen MA, Li X, Lee YC,
Ortiz A, Kowalczyk AP, Yu-Lee LY and Lin SH: Cadherin-11
endocytosis through binding to clathrin promotes
cadherin-11-mediated migration in prostate cancer cells. J Cell
Sci. 128:4629–4641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ortiz A, Lee YC, Yu G, Liu HC, Lin SC,
Bilen MA, Cho H, Yu-Lee LY and Lin SH: Angiomotin is a novel
component of cadherin-11/β-catenin/p120 complex and is critical for
cadherin-11-mediated cell migration. FASEB J. 3:1080–1091. 2015.
View Article : Google Scholar
|
|
33
|
Clay MR and Halloran MC: Cadherin 6
promotes neural crest cell detachment via F-actin regulation and
influences active Rho distribution during epithelial-to-mesenchymal
transition. Development. 141:2506–2515. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bravo-Cordero JJ, Moshfegh Y, Condeelis J
and Hodgson L: Live cell imaging of RhoGTPase biosensors in tumor
cell. Methods Mol Biol. 1046:359–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sancisi V, Gandolfi G, Ragazzi M, Nicoli
D, Tamagnini I, Piana S and Ciarrocchi A: Cadherin 6 is a new RUNX2
target in TGF-β signalling pathway. PLoS One. 8:e754892013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bringuier PP, Schalken JA, Hervieu V and
Giroldi LA: Involvement of orphan nuclear receptor COUP-TFII in
cadherin-6 and cadherin-11 regulation: Implications in development
and cancer. Mech Dev. 136:64–72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Satcher RL, Pan T, Cheng CJ, Lee YC, Lin
SC, Yu G, Li X, Hoang AG, Tamboli P, Jonasch E, et al: Cadherin-11
in renal cell carcinoma bone metastasis. PLoS One. 9:e898802014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wells CD, Fawcett JP, Traweger A, Yamanaka
Y, Goudreault M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, et
al: A Rich1/Amot complex regulates the Cdc42 GTPase and
apical-polarity proteins in epithelial cells. Cell. 125:535–548.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ernkvist M, Luna Persson N, Audebert S,
Lecine P, Sinha I, Liu M, Schlueter M, Horowitz A, Aase K, Weide T,
et al: The Amot/Patj/Syx signaling complex spatially controls RhoA
GTPase activity in migrating endothelial cells. Blood. 113:244–253.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yi C, Troutman S, Fera D,
Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, Shimono A,
Speicher DW, Marmorstein R, et al: A tight junction-associated
Merlin-angiomotin complex mediates Merlin's regulation of mitogenic
signaling and tumor suppressive functions. Cancer Cell. 19:527–540.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feltes CM, Kudo A, Blaschuk O and Byers
SW: An alternatively spliced cadherin-11 enhances human breast
cancer cell invasion. Cancer Res. 62:6688–6697. 2002.PubMed/NCBI
|
|
43
|
Kiener HP, Stipp CS, Allen PG, Higgins JM
and Brenner MB: The cadherin-11 cytoplasmic juxtamembrane domain
promotes alpha-catenin turnover at adherens junctions and
intercellular motility. Mol Biol Cell. 17:2366–2375. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu M, Xu T, Zhou Y, Lu H and Gu Z:
Pressure and inflammatory stimulation induced increase of
cadherin-11 is mediated by PI3K/Akt pathway in synovial fibroblasts
from temporomandibular joint. Osteoarthritis Cartilage.
21:1605–1612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao Y, Foster R, Yang X, Feng Y, Shen JK,
Mankin HJ, Hornicek FJ, Amiji MM and Duan Z: Up-regulation of CD44
in the development of metastasis, recurrence and drug resistance of
ovarian cancer. Oncotarget. 6:9313–9326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu H, Tian Y, Yuan X, Liu Y, Wu H, Liu Q,
Wu GS and Wu K: Enrichment of CD44 in basal-type breast cancer
correlates with EMT, cancer stem cell gene profile, and prognosis.
Onco Targets Ther. 9:431–444. 2016.PubMed/NCBI
|
|
47
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ghuwalewala S, Ghatak D, Das P, Dey S,
Sarkar S, Alam N, Panda CK and Roychoudhury S: CD44(high)CD24(low)
molecular signature determines the Cancer Stem Cell and EMT
phenotype in oral squamous cell carcinoma. Stem Cell Res.
16:405–417. 2016. View Article : Google Scholar : PubMed/NCBI
|
